Clinical trials: Clostridium Difficile Infections
Clostridiodies Difficile Infections
MTC Versus FMT in for RCDI
Investigating four different treatment of MTC or FMT
- Trial name
- NCT05911997
- Testing
- MTC 01, Fecal Microbiota Transplantation (FMT)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer, Urinary Tract Infection
Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy
The aim of this study is to determine whether antibiotics prophylaxis at the time of urinary catheter removal decreases the number of symptomatic urinary tract infections in patients after radical prostatectomy.
- Conditions
- Prostate Cancer, Urinary Tract Infection, Clostridium Difficile
- Trial name
- Abx (NCT02247960)
- Testing
- Ciprofloxacin
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- University of Rochester
Clostridium Difficile Infection
Clostridium Difficile Vaccine Efficacy Trial
The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium…
- Trial name
- Clover (NCT03090191)
- Testing
- Clostridium difficile vaccine
- Where
- 426 sites in United States, Argentina and 21 more
- Volunteers
- 17,535 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile, Clostridium Difficile Infection
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Clostridium Difficile, Clostridium Difficile Infection, Microbiome, CDI
- Trial name
- NCT04100603
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Clostridium Difficile Infections
Treatment of CDI and Recurrence With Fecal Microbiota Transplant Using Promicrobioma
The increasing inappropriate use of antimicrobials, in addition to increasing selective pressure and inducing environmental resistance, is also a risk factor for the development of Clostridioides difficile infection (CDI).
- Trial name
- NCT06107569
- Testing
- Fecal microbiota transplant (Promicrobioma), Antibiotic
- Volunteers
- 24 people
- Sponsor
- Hospital Universitario Evangelico de Curitiba
Clostridium Enterocolitis, Diarrhea
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea
Approximately 520 patients will be entered into this study taking place throughout Australia and Europe. This study aims to determine if an investigational drug is safe and effective for treating symptoms of C.
- Trial name
- NCT00196794
- Testing
- Tolevamer potassium-sodium (GT267-004)
- Where
- 138 sites in Australia, Austria and 12 more
- Volunteers
- 520 people
- Sponsor
- Genzyme, a Sanofi Company
Cross Infection, Clostridium Difficile Infection
Evaluation of the Cost of a Nosocomial Infection With Clostridium Difficile
Clostridium difficile is the first cause of nosocomial infectious diarrhea, due to its mode of transmission and its resistance in the environment.
- Trial name
- NCT03025672
- Volunteers
- 10,445 people
- Sponsor
- Lille Catholic University
Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection
Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile
The purpose of this study is to see if stool transplant performed by colonoscopy is effective at treating recurrent Clostridium difficile (C. diff) infection of the colon.
- Trial name
- NCT03562741
- Testing
- Fecal Microbiota Transplantation
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Krunal Patel
Clostridium Difficile Infection
Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea
This clinical study is conducted to assess the efficacy of cadazolid compared to vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).
- Trial name
- NCT01983683
- Testing
- Cadazolid, Vancomycin
- Volunteers
- 631 people
- Sponsor
- Actelion
Clostridium Difficile Infection, C.Difficile Diarrhea
The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation
The primary objective of this study is to compare the gut microbiota and clinical outcomes of oral FMT during antibiotic treatment, immediately following antibiotic treatment, and placebo.
- Conditions
- Clostridium Difficile Infection, C.Difficile Diarrhea, CDI
- Trial name
- GRAFT (NCT03621657)
- Testing
- Low Dose FMT Capsule DE, Single Dose FMT Capsule DE
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Wisconsin, Madison
Clostridium Difficile Infection, Diarrhea
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
This study will further evaluate the ACAM-CDIFF™ vaccine in a population of middle-aged to elderly individuals at risk of exposure to Clostridium difficile because of impending hospitalization or residence in a care facility.
- Trial name
- NCT01230957
- Testing
- Clostridium difficile toxoids A and B (Low-dose with adjuvant), Clostridium difficile toxoids A and B (Low-dose without adjuvant), Clostridium difficile toxoids A and B (high-dose with adjuvant)
- Where
- 30 sites in United States
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Clostridium Difficile Infection
Validation of a Prediction Score for Recurrent C. Difficile Infection: Implementation for Treatment Algorithm Strategies
The objective of the present study is to derive a high-risk R-ICD prediction rule and a prospective implementation of this prediction rule.
- Trial name
- Clostri_Score (NCT04187430)
- Testing
- Retrospective, Prospective
- Where
- Spain
- Volunteers
- 513 people
- Sponsor
- Emilio Bouza
Clostridium Difficile Infection, Clostridioides Difficile Infection
Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection
Clostridioides difficile (CD) infection (CDI) is a global health threat with an urgent need for new treatment strategies. Faecal microbiota transplantation (FMT) is effective for recurrent Clostridioides difficile infection…
- Trial name
- EarlyFMT (NCT04885946)
- Testing
- Fecal microbiota transplantion (FMT)
- Where
- Denmark
- Volunteers
- 42 people
- Sponsor
- Christian Lodberg Hvas
Recurrent C. Difficile Infection
Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)
To establish optimal dosing of lyophilized Fecal microbiota transplantation (FMT) product in the treatment of recurrent C. difficile infection
- Trial name
- NCT03298048
- Testing
- Low fecal microbiota dose, Mid fecal microbiota dose, High fecal microbiota dose
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- The University of Texas Health Science Center, Houston
Clostridium Difficile
Fecal Microbiota Transplantation (FMT) in Clostridium Difficile Infection (CDI) Not Responding to Antibiotics
Purpose: To study the changes in the microbiome and stool composition in patients with Clostridium Difficile Infection (CDI) who undergo Fecal Microbiota Transplantation (FMT), along with changes in their clinical characteristics.
- Trial name
- FMT (NCT03117582)
- Testing
- Stool specimen
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of North Carolina, Chapel Hill
Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Xylitol Use for Decolonization of C. Difficile in Patients With IBD
This is a randomized, placebo-controlled, dose-ranging study to assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in IBD patients.
- Trial name
- NCT05852587
- Testing
- Xylitol
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Brigham and Women's Hospital
Clostridium Difficile, Spinal Cord Injury
Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury
The primary purpose of this study is to compare the clinical outcomes of cure and recurrence of Clostridium difficile infection in spinal cord injured patients who are treated with oral Fidaxomicin vs. oral Vancomycin.
- Trial name
- NCT02355938
- Testing
- Fidaxomicin 200 mg, Vancomycin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Baylor College of Medicine
Clostridium Difficile Colitis
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
It has been shown that restoration of the normal makeup of the bowel bacterial population is the most effective way to treat recurrent colitis due to Clostridium difficile.
- Trial name
- NCT02127398
- Testing
- fecal microbiota
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Duke University
Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
The purpose of this study is to evaluate the ability of oral vancomycin in preventing Clostridioides difficile infection (CDI) in patients that are simultaneously receiving antibiotics.
- Trial name
- NCT07221708
- Testing
- Vancomycin (POC)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Clostridium Difficile
Randomized Clinical Trial of Standard FMT Treatments
This is a single center, randomized, parallel assignment, double-blinded, efficacy and safety study to be conducted in subjects with recurrent C. difficile Infection (RCDI).
- Trial name
- FMT (NCT04729790)
- Testing
- PRIM-DJ2727
- Sponsor
- The University of Texas Health Science Center, Houston